Delaware
|
001-37763
|
20-0709285
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
5201 Interchange Way, Louisville, KY
|
|
40229
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
TPB
|
New York Stock Exchange
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Emerging growth company ☐
|
Item 2.02. |
Results of Operations and Financial Condition.
|
Item 7.01. |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
|
|
|
|
|
Press Release dated July 27, 2022
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|
|
|
|
||
Dated: July 27, 2022
|
By:
|
/s/ Brittani N. Cushman
|
|
|
|
Brittani N. Cushman
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
|
|
• |
Net sales decreased 16.1 percent to $102.9 million
|
|
o |
Combined net sales for Zig-Zag and Stoker’s Products demonstrated resilience decreasing 0.9 percent for the quarter
|
|
o |
NewGen net sales declined by 45.1 percent (declined 2.1 percent sequentially)
|
|
• |
Gross profit decreased 14.2 percent to $51.5 million
|
|
• |
Net income decreased 64.7 percent to $5.4 million
|
|
• |
Adjusted EBITDA decreased 17.6 percent to $24.7 million (see Schedule A for a reconciliation to net income)
|
|
• |
Diluted EPS of $0.30 and Adjusted Diluted EPS of $0.70 as compared to $0.73 and $0.84 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
|
• |
$0.3 million of restructuring expenses compared to none in the previous year
|
|
• |
$0.9 million of ERP / CRM scoping expenses and duplicative system costs compared to none in the previous year
|
|
• |
$1.5 million of stock options, restricted stock and incentive expense compared to $2.8 million in the year-ago period
|
|
• |
$0.4 million of transaction expenses compared to $0.7 million in the year-ago period
|
|
• |
$2.0 million of FDA PMTA-related expenses compared to $0.6 million in the year-ago period
|
|
• |
$1.6 million from the accounting consolidation of Turning Point Brands Canada compared to $1.1 in the year-ago period with the increase driven by the inclusion of a full quarter
of the DVW acquisition in the current period
|
|
• |
Zig-Zag Products sales of $193 to $200 million (compared to previous outlook of $193 to $203 million)
|
|
• |
Stoker’s Products sales of $127 to $133 million
|
|
• |
Consolidated adjusted EBITDA of $97 to $103 million
|
Three Months Ended June 30,
|
||||||||
2022
|
2021
|
|||||||
Net sales
|
$
|
102,925
|
$
|
122,643
|
||||
Cost of sales
|
51,456
|
62,670
|
||||||
Gross profit
|
51,469
|
59,973
|
||||||
Selling, general, and administrative expenses
|
33,323
|
35,094
|
||||||
Operating income
|
18,146
|
24,879
|
||||||
Interest expense, net
|
5,144
|
5,522
|
||||||
Investment loss (income)
|
6,227
|
(110
|
)
|
|||||
Income before income taxes
|
6,775
|
19,467
|
||||||
Income tax expense
|
1,569
|
4,424
|
||||||
Consolidated net income
|
5,206
|
15,043
|
||||||
Net loss attributable to non-controlling interest
|
(218
|
)
|
(312
|
)
|
||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||
Basic income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.30
|
$
|
0.81
|
||||
Diluted income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.30
|
$
|
0.73
|
||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
18,063,259
|
18,975,522
|
||||||
Diluted
|
21,443,279
|
22,489,662
|
||||||
Supplemental disclosures of statements of income information:
|
||||||||
Excise tax expense
|
$
|
6,141
|
$
|
7,687
|
||||
FDA fees
|
$
|
171
|
$
|
180
|
ASSETS
|
(unaudited)
June 30,
2022
|
December 31,
2021
|
||||||
Current assets:
|
||||||||
Cash
|
$
|
107,429
|
$
|
128,320
|
||||
Accounts receivable, net of allowances of $161 in 2022 and $262 in 2021
|
9,177
|
6,496
|
||||||
Inventories
|
115,129
|
87,607
|
||||||
Other current assets
|
27,353
|
26,746
|
||||||
Total current assets
|
259,088
|
249,169
|
||||||
Property, plant, and equipment, net
|
22,376
|
18,650
|
||||||
Deferred income taxes
|
2,111
|
1,363
|
||||||
Right of use assets
|
13,749
|
15,053
|
||||||
Deferred financing costs, net
|
335
|
388
|
||||||
Goodwill
|
162,385
|
162,333
|
||||||
Other intangible assets, net
|
86,566
|
87,485
|
||||||
Master Settlement Agreement (MSA) escrow deposits
|
29,224
|
31,720
|
||||||
Other assets
|
28,475
|
35,399
|
||||||
Total assets
|
$
|
604,309
|
$
|
601,560
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
14,436
|
$
|
7,361
|
||||
Accrued liabilities
|
34,560
|
32,937
|
||||||
Other current liabilities
|
38
|
38
|
||||||
Total current liabilities
|
49,034
|
40,336
|
||||||
Notes payable and long-term debt
|
415,410
|
414,172
|
||||||
Lease liabilities
|
11,934
|
13,336
|
||||||
Total liabilities
|
476,378
|
467,844
|
||||||
Commitments and contingencies
|
||||||||
Stockholders' equity:
|
||||||||
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,797,735 issued shares and 17,890,441 outstanding shares at June
30, 2022, and 19,690,884 issued shares and 18,395,476 outstanding shares at December 31, 2021
|
198
|
197
|
||||||
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
Additional paid-in capital
|
110,563
|
108,811
|
||||||
Cost of repurchased common stock
|
||||||||
(1,907,294 shares at June 30, 2022 and 1,295,408 shares at December 31, 2021)
|
(68,287
|
)
|
(48,869
|
)
|
||||
Accumulated other comprehensive loss
|
(2,064
|
)
|
(195
|
)
|
||||
Accumulated earnings
|
85,641
|
71,460
|
||||||
Non-controlling interest
|
1,880
|
2,312
|
||||||
Total stockholders' equity
|
127,931
|
133,716
|
||||||
Total liabilities and stockholders' equity
|
$
|
604,309
|
$
|
601,560
|
Six Months Ended June 30,
|
|||||||||
2022
|
2021
|
||||||||
Cash flows from operating activities:
|
|||||||||
Consolidated net income
|
$
|
15,977
|
$
|
26,570
|
|||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
|||||||||
Loss on extinguishment of debt
|
-
|
5,706
|
|||||||
Gain on sale of property, plant, and equipment
|
(8
|
)
|
(2
|
)
|
|||||
Depreciation expense
|
1,750
|
1,546
|
|||||||
Amortization of other intangible assets
|
919
|
954
|
|||||||
Amortization of deferred financing costs
|
1,291
|
1,251
|
|||||||
Deferred income tax (benefit) expense
|
(146
|
)
|
1,027
|
||||||
Stock compensation expense
|
2,661
|
4,263
|
|||||||
Noncash lease income
|
(6
|
)
|
(19
|
)
|
|||||
Loss (gain) on investments
|
6,258
|
(34
|
)
|
||||||
Changes in operating assets and liabilities:
|
|||||||||
Accounts receivable
|
(2,673
|
)
|
3,955
|
||||||
Inventories
|
(27,499
|
)
|
(12,007
|
)
|
|||||
Other current assets
|
(598
|
)
|
813
|
||||||
Other assets
|
624
|
599
|
|||||||
Accounts payable
|
7,240
|
1,423
|
|||||||
Accrued liabilities and other
|
1,359
|
1,370
|
|||||||
Net cash provided by operating activities
|
$
|
7,149
|
$
|
37,415
|
|||||
Cash flows from investing activities:
|
|||||||||
Capital expenditures
|
$
|
(5,694
|
)
|
$
|
(2,170
|
)
|
|||
Acquisitions, net of cash acquired
|
-
|
(3,419
|
)
|
||||||
Payments for investments
|
-
|
(8,657
|
)
|
||||||
Restricted cash, MSA escrow deposits
|
(10,078
|
)
|
(20,147
|
)
|
|||||
Proceeds on the sale of property, plant and equipment
|
63
|
2
|
|||||||
Net cash used in investing activities
|
$
|
(15,709
|
)
|
$
|
(34,391
|
)
|
|||
Cash flows from financing activities:
|
|||||||||
Proceeds from Senior Secured Notes
|
$
|
-
|
$
|
250,000
|
|||||
Payments of 2018 first lien term loan
|
-
|
(130,000
|
)
|
||||||
Settlement of interest rate swaps
|
-
|
(3,573
|
)
|
||||||
Payment of dividends
|
(2,181
|
)
|
(2,006
|
)
|
|||||
Payments of financing costs
|
-
|
(6,921
|
)
|
||||||
Exercise of options
|
475
|
886
|
|||||||
Redemption of options
|
(155
|
)
|
(2,111
|
)
|
|||||
Redemption of performance restricted stock units
|
(1,228
|
)
|
-
|
||||||
Common stock repurchased
|
(19,418
|
)
|
(14,086
|
)
|
|||||
Net cash provided by (used in) financing activities
|
$
|
(22,507
|
)
|
$
|
92,189
|
||||
Net (decrease) increase in cash
|
$
|
(31,067
|
)
|
$
|
95,213
|
||||
Effect of foreign currency translation on cash
|
$
|
56
|
$
|
315
|
|||||
Cash, beginning of period:
|
|||||||||
Unrestricted
|
128,320
|
41,765
|
|||||||
Restricted
|
15,155
|
35,074
|
|||||||
Total cash at beginning of period
|
143,475
|
76,839
|
|||||||
Cash, end of period:
|
|||||||||
Unrestricted
|
107,429
|
157,474
|
|||||||
Restricted
|
5,035
|
14,893
|
|||||||
Total cash at end of period
|
$
|
112,464
|
$
|
172,367
|
Three Months Ended
June 30,
|
||||||||
2022
|
2021
|
|||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
5,424
|
$
|
15,355
|
||||
Add:
|
||||||||
Interest expense, net
|
5,144
|
5,522
|
||||||
Income tax expense
|
1,569
|
4,424
|
||||||
Depreciation expense
|
879
|
758
|
||||||
Amortization expense
|
456
|
479
|
||||||
EBITDA
|
$
|
13,472
|
$
|
26,538
|
||||
Components of Adjusted EBITDA
|
||||||||
Corporate restructuring (a)
|
270
|
-
|
||||||
ERP/CRM (b)
|
861
|
-
|
||||||
Stock options, restricted stock, and incentives expense (c)
|
1,502
|
2,764
|
||||||
Transactional expenses (d)
|
364
|
702
|
||||||
FDA PMTA (e)
|
1,957
|
-
|
||||||
Non-cash asset impairment (f)
|
6,300
|
-
|
||||||
Adjusted EBITDA
|
$
|
24,726
|
$
|
30,004
|
(a)
|
Represents costs associated with corporate restructuring, including severance.
|
(b)
|
Represents cost associated with scoping new ERP and CRM systems.
|
(c)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units.
|
(d)
|
Represents the fees incurred for transaction expenses.
|
(e)
|
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
(f)
|
Represents impairment of investment in dosist.
|
Three Months Ended
June 30,
|
||||||||
|
2022
|
2021
|
||||||
GAAP EPS
|
$
|
0.30
|
$
|
0.73
|
||||
Corporate restructuring (a)
|
0.01
|
-
|
||||||
ERP/CRM (b)
|
0.03
|
-
|
||||||
Stock options, restricted stock, and incentives expense (c)
|
0.05
|
0.09
|
||||||
Transactional expenses (d)
|
0.01
|
0.02
|
||||||
FDA PMTA (e)
|
0.07
|
-
|
||||||
Non-cash asset impairment (f)
|
0.23
|
-
|
||||||
Tax (expense) benefit (g)
|
0.00
|
(0.01
|
)
|
|||||
Adjusted diluted EPS
|
$
|
0.70
|
$
|
0.84
|
Totals may not foot due to rounding
|
(a)
|
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
(b)
|
Represents cost associated with scoping new ERP and CRM systems tax effected at the quarterly tax rate.
|
(c)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
(d)
|
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
(e)
|
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
(f)
|
Represents impairment of investment in dosist tax effected at the quarterly tax rate.
|
(g)
|
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2022 and 2021.
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
NewGen Products
|
||||||||||||||||||||||||||||
|
2nd Quarter
2022
|
2nd Quarter
2021
|
2nd Quarter
2022
|
2nd Quarter
2021
|
2nd Quarter
2022
|
2nd Quarter
2021
|
2nd Quarter
2022
|
2nd Quarter
2021
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Net sales
|
$
|
102,925
|
$
|
122,643
|
$
|
46,226
|
$
|
47,202
|
$
|
33,588
|
$
|
33,369
|
$
|
23,111
|
$
|
42,072
|
||||||||||||||||
|
||||||||||||||||||||||||||||||||
Gross profit
|
$
|
51,469
|
$
|
59,973
|
$
|
26,430
|
$
|
27,743
|
$
|
18,079
|
$
|
18,146
|
$
|
6,960
|
$
|
14,084
|
||||||||||||||||
|
||||||||||||||||||||||||||||||||
Operating income
|
$
|
18,146
|
$
|
24,879
|
$
|
18,503
|
$
|
21,338
|
$
|
13,378
|
$
|
13,826
|
$
|
552
|
$
|
1,657
|
||||||||||||||||
Adjustments:
|
||||||||||||||||||||||||||||||||
Corporate restructuring
|
270
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
ERP/CRM
|
861
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||||
Transactional expenses
|
364
|
702
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
FDA PMTA
|
1,957
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
Adjusted operating income
|
$
|
21,598
|
$
|
25,581
|
$
|
18,503
|
$
|
21,338
|
$
|
13,378
|
$
|
13,826
|
$
|
552
|
$
|
1,657
|